Rupee ki girawat, Pharma ke liye treasure!
India ki pharma companies ke liye FY27 ek zabardast saal ho sakta hai, kyunki apne Indian Rupee ki girawat unki earnings ko kaafi boost de sakti hai, especially un companies ko jin ka export business bada hai. Elara Securities ka andaaza hai ki currency ke is support se reported revenues 5% tak aur EBITDA toh 15% tak badh sakta hai. Yeh isliye kyunki pharma sector bahar ke markets par kaafi depend karta hai, aur zyada tar income abroad se hi aati hai.
90% se zyada revenue abroad kamane wali Aurobindo Pharma aur Gland Pharma jaisi companies toh maalamaal ho sakti hain. Iske alawa 11 aur companies, jisme Zydus Lifesciences bhi hai, woh bhi 70% se zyada revenue export se laati hain.
Rupee pichle kuch mahino se girawat dikha raha hai. Agar yeh trend chalta raha, toh FY27 mein yeh FY26 ke muqable 6% se 15% tak kam ho sakta hai. Iska ek reason Middle East mein chal rahi tensions bhi hai, jisne Brent crude prices ko $120 dollar per barrel ke aas paas pahuncha diya hai.
Kon karega kamaal aur kaun phasega?
Elara Securities ne yeh bhi bataya ki lagbhag sabhi pharma companies ko iska fayda milega, kyunki unka revenue mix global hai. Agar foreign currencies rupee ke muqable 5.8% zyada strong rahin, toh revenues mein 1% se 5% tak ka izafa ho sakta hai. Biocon, Granules India, Aurobindo Pharma, aur Gland Pharma ko is currency movement ka sabse zyada fayda milne ki ummeed hai, kyunki unka global operations bahut bada hai.
Dusri taraf, jo companies sirf India mein business karti hain, jaise Eris Lifesciences aur Mankind Pharma, unko shayad thoda pressure face karna padega, kyunki import karna mehenga ho jayega aur overseas expenses bhi badh jayenge.
Currency ke alawa bhi hain risks!
Lekin, is currency boost ke saath kuch risks bhi jude hain. Crude oil ke badhte prices sirf rupee ko hi nahi, balki drug ingredients (APIs) banane mein use hone wale petrochemical derivatives ka cost bhi badha rahe hain. Is se currency se hone wala profit kam ho sakta hai.
Sun Pharma jaisi companies, jinka US market mein kaafi business hai, unke liye wahan pricing pressure aur US FDA ki strict checking bhi ek chinta ka vishay bani hui hai, phir chahe rupee ka kuch bhi ho.
Iske alawa, export-heavy companies ko currency ka fayda toh milega, par agar global economy slow ho gayi ya kisi bade export market mein regulations change ho gaye, toh nuksan ho sakta hai.
Valuation aur Outlook
Investors ke liye, export-oriented companies jaise Aurobindo Pharma (P/E around 18x) aur Granules India (15x) abhi kaafi attractive lag rahe hain, unke potential currency-driven profit boost ko dekhte hue. Wahi, Biocon (40x P/E) ya Eris Lifesciences (35x P/E) jaise higher-valued peers ke liye growth ke drivers alag ho sakte hain.
Sun Pharma (25x P/E) aur Dr. Reddy’s Laboratories (22x P/E) ka profile balanced hai, kyunki unka domestic aur export dono mein acha presence hai. Analysts expect karte hain ki FY27 tak pharma exporters ke liye currency advantage ek bada support bana rahega.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
